Published in Adv Healthc Mater on March 17, 2016
Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal. Immunol Rev (2016) 0.78
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation therapy. Biomaterials (2017) 0.76
Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites. Theranostics (2017) 0.75
Nanoparticle Design Strategies for Effective Cancer Immunotherapy. J Biomed (Syd) (2017) 0.75
Cell membrane-derived nanoparticles: emerging clinical opportunities for targeted drug delivery. Nanomedicine (Lond) (2017) 0.75
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med (2007) 12.73
Impact of nanotechnology on drug delivery. ACS Nano (2009) 6.87
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol (2012) 4.84
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A (1998) 2.50
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev (2010) 2.23
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 2.13
The multifaceted functions of neutrophils. Annu Rev Pathol (2013) 1.97
Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm (2003) 1.86
Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release (2011) 1.68
Neutrophils mediate antibody-induced antitumor effects in mice. Blood (2013) 1.66
Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils. Nat Nanotechnol (2014) 1.63
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov (2014) 1.61
Analysis on the current status of targeted drug delivery to tumors. J Control Release (2012) 1.48
Oculocutaneous albinism types 1 and 3 are ER retention diseases: mutation of tyrosinase or Tyrp1 can affect the processing of both mutant and wild-type proteins. FASEB J (2001) 1.33
Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. ACS Nano (2009) 1.33
Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today (2010) 1.22
Combination strategies to enhance antitumor ADCC. Immunotherapy (2012) 1.12
The mouse brown (b) locus protein has dopachrome tautomerase activity and is located in lysosomes in transfected fibroblasts. J Cell Sci (1993) 1.11
Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway. Int J Oncol (2010) 1.09
Photodynamic nanomedicine in the treatment of solid tumors: perspectives and challenges. J Control Release (2013) 1.05
Delivery of nanoparticle: complexed drugs across the vascular endothelial barrier via caveolae. IUBMB Life (2011) 1.05
Targeting tumors with nanobodies for cancer imaging and therapy. J Control Release (2013) 1.04
Sorting and secretion of a melanosome membrane protein, gp75/TRP1. J Invest Dermatol (1997) 1.03
Stimuli-sensitive nanopreparations for combination cancer therapy. J Control Release (2014) 0.92
New trends in guided nanotherapies for digestive cancers: A systematic review. J Control Release (2015) 0.88
Photodynamic therapy in melanoma--an update. J Physiol Pharmacol (2012) 0.87
Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies. Anticancer Res (2008) 0.84
Neutrophil-Mediated Delivery of Therapeutic Nanoparticles across Blood Vessel Barrier for Treatment of Inflammation and Infection. ACS Nano (2015) 0.81
Targeted nanotheranostics for personalized cancer therapy. Expert Opin Drug Deliv (2012) 0.79
Neutrophils in antibody-based immunotherapy of cancer. Expert Opin Biol Ther (2008) 0.79
Cell membrane-formed nanovesicles for disease-targeted delivery. J Control Release (2016) 0.78
Advancement in multifunctional nanoparticles for the effective treatment of cancer. Expert Opin Drug Deliv (2012) 0.77